Luxdegalutamide

Cat. No.: HY-153342

CAS No.: 2750830-09-0

Molecular Formula: $C_{45}H_{54}FN_7O_6$

Molecular Weight: 807.95

Target: PROTACs; Androgen Receptor

Pathway: PROTAC; Vitamin D Related/Nuclear Receptor

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (123.77 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.2377 mL	6.1885 mL	12.3770 mL
	5 mM	0.2475 mL	1.2377 mL	2.4754 mL
	10 mM	0.1238 mL	0.6189 mL	1.2377 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (3.09 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations[1].

REFERENCES

[1]. Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)[J]. 2023.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA